
BGE-100
CNS-penetrant NLRP3 inhibitor
Targeting neuroinflammation
NLRP3 is a critical component of the inflammasome, a protein complex that assembles in response to infection and tissue damage and results in inflammation needed to promote healing. However, chronic inflammasome activation leads to pathologic inflammation that drives a vast number of immunologic and fibrotic disorders.
Analysis of BioAge’s proprietary longitudinal human aging cohorts revealed that NLRP3 levels rise with age and are associated with all-cause mortality.
BioAge has discovered a family of chemically novel NLRP3 inhibitors. BGE-100 is our most advanced program. It is both potent and highly brain penetrant, with potential to address a range of neurodegenerative conditions driven by neuroinflammation.
BGE-100 corrects chronic inflammasome activation
that is associated with aging and drives a broad
range of diseases
BGE-100 corrects chronic
inflammasome activation that is
associated with aging and drives a
broad range of diseases
BGE-100 corrects chronic
inflammasome activation that is
associated with aging and drives a
broad range of diseases
BGE-100 corrects chronic inflammasome activation
that is associated with aging and drives a broad
range of diseases
BGE-100 corrects chronic
inflammasome activation that is
associated with aging and drives a
broad range of diseases
BGE-100 corrects chronic
inflammasome activation that is
associated with aging and drives a
broad range of diseases
Acute inflammation to enable immune response to pathogen

Prolonged inflammation, even in the absence of pathogen
Acute inflammation to enable immune response to pathogen

Prolonged inflammation, even in the absence of pathogen
BioAge collaborator spotlight
Chronic activation of the NLRP3 inflammasome is associated with aging and is a major contributor to the pathologic inflammation that drives or exacerbates multiple metabolic, immunologic, and fibrotic disorders, as well as neurodegenerative conditions such as Parkinson’s and Alzheimer’s. Inhibition of NLRP3 using small-molecules thus has the potential to treat a broad spectrum of age-related diseases.
Rebecca Coll, PhD
Wellcome Wolfson Institute for Experimental Medicine
Queen's University Belfast